Jurgen Götz

Lesleigh Green - Bill and Nancy Green Endowed Chair in Dementia Research (2023-); Graduate, Australian Institute of Company Directors (GAICD) (2021); Fellow, Australian Academy of Health and Medical Science (FAHMS) (2016); Foundation Chair of Dementia Research, Queensland Brain Institute (QBI), University of Queensland (2012-).

I am an internationally renowned expert in transgenic mouse models of Alzheimer’s disease (AD). I generated the first tau transgenic mouse model with an early AD phenotype (EMBO J 1995). Together with Dr. Hutton, I published the first mouse model with NFT formation (JBC 2001a). I provided long-sought evidence for the amyloid cascade hypothesis by combining a transgenic and a transplantation approach (Science 2001). This highly cited work was accompanied by an Editorial in the same issue of Science, and selected as Milestone Paper by Alzforum (alzforum.org). I demonstrated a role for FGF5 in the hair growth cycle (Cell 1994), worked on prions (Cell 1998), and showed that the catalytic subunit of PP2A is essential for development (PNAS 1998) and that PP2A is a key enzyme in tau phosphorylation (JBC 2001b, AmJPathol 2003). I established the first in vitro model of Aβ-induced tau filament formation (JBC 2003). Using functional genomics, I provided evidence for mitochondrial dysfunction and a role for glyoxalase in AD (PNAS 2003, JBC 2005, Proteomics 2006, PNAS 2009). I identified a novel function of tau in targeting the kinase Fyn to the to mediate Aβ toxicity (Cell 2010), and a role for Fyn in causing de novo protein synthesis of tau (EMBO J 2017). I also developed a novel ultrasound-based treatment of amyloid- and tau-depositing mice that we are currently developing for clinical application in AD patients (Science Transl Med 2015, Brain 2017, MolPsych 2021). This discovery elicited an overwhelming response from media (numerous media appearances calculated by the UQ Advancement Office to be worth $1m in advertising space rates in the two weeks following the 2015 publication) and the general public (2,000 e-mail requests from patients within four months of publication.

• Highly cited researcher (Clarivate, 2021, 2022)
• 67 of my publications have been cited in 1,121 patent documents: 659 granted patents; 431 patent applications and 31 searches.Jurisdictions include: World Intellectual Property Organization; United States Patent and Trademark Office; and the European Patent Office (The Lens,April 2022).
• Expertscape.com ranking (Top 0.02% of 182,647 published authors worldwide in AD:

225 peer-reviewed articles (3 Cell, 1 Science, 1 Science Transl Med, 3 Neuron, 8 PNAS, 9 EMBO J, 7 J. Biol. Chem., 3 Mol Psych, 5 Acta Neuropathol, 1 Lancet, 4 Nature Rev Neurosci, 3 Nature Rev Neurol, 1 Nature Rev Drug Disc, 3 Nature Prot, 5 Theranostics), Web of Science highly cited papers in the fields of Neuroscience & Behavior (5), Biology & Biochemistry, Pharmacology & Toxicology, and Molecular Biology & Genetics. >27,800 times (Google Scholar). Total Impact factor: 2,000; h-index: 86 (78 papers >100 cit).

https://scholar.google.com.au/citations?user=67UrhCQAAAAJ&hl=en